DEA HHS Extend Telemedicine Prescribing to End of 2026 Globally

US DEA and HHS have allowed telemedicine prescribing flexibilities to remain in effect until 2026, thus securing remote access for behavioral health and other chronic conditions in the midst of policy debates. Providers get the assurance of stability thanks to this move while the final long, term rules are being developed, at the same time digital health is recognized as a maturing sector.

The American Hospital Association points out a workforce “reinvention” in 2026, with hospitals reworking their staffing through tech, supported team care to fight the strains. Amazon One Medical’s Health Insights beta gives you a personalized lab results letter, while CareDx’s AlloHeme AI can detect AML/MDS relapse post, therapy even earlier than the standard methods.

LifeScan has teamed up with i, SENS for the OneTouch CGM, both brands together reinforcing their position in the glucose management leadership. AccurKardias AI, ECG has identified the presence of aortic stenosis 4.5 years before intervention, thus making a tremendous improvement in just the predictions. These show how advanced technologies such as AI are reshaping healthcare at the point of care.
Even as the focus becomes clearer, capital flows keep the pace. On a global scale, there are implications such as the wider telehealth adoption that helps in providing better access to the areas that lack sufficient services.